Terms: = Prostate cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Prognosis
4 results:
1. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.
Nilsson C; Linde F; Hulegårdh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jädersten M; Björkvall CK; Möllgård L; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Haematologica; 2023 Apr; 108(4):1015-1025. PubMed ID: 36005563
[TBL] [Abstract] [Full Text] [Related]
2. High expression of npm1 via the Wnt/β-catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma.
Ruan Y; Xu H; Ji X
Clin Exp Pharmacol Physiol; 2022 Apr; 49(4):525-535. PubMed ID: 35108408
[TBL] [Abstract] [Full Text] [Related]
3. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With prostate cancer.
Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
[TBL] [Abstract] [Full Text] [Related]
4. Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis.
Ching RH; Lau EY; Ling PM; Lee JM; Ma MK; Cheng BY; Lo RC; Ng IO; Lee TK
Oncotarget; 2015 Dec; 6(41):43483-95. PubMed ID: 26536659
[TBL] [Abstract] [Full Text] [Related]
